Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) up 16.2% since last earnings report: Can it continue?
It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 16.2% in that time frame, outperforming the S&P 500. But investors have to be ...
Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs.
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 9 Stocks Crushing the Market With Surging Returns. Recursion ...
Short interest data from late May indicates varying investor feelings in the healthcare sector, with strong bearish bets concentrated on speculative biotech plays like Recursion Pharmaceuticals (RXRX) ...
View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation ...
This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of ...
Never heard of it? Don't sweat it. Plenty of people haven't. Its $2 billion market capitalization doesn't turn many heads. Losses that are persistently greater than its scant revenue don't draw a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results